{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:44:12Z","timestamp":1788349452707,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["27842"],"award-info":[{"award-number":["27842"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Psoriasis is a common, chronic, and non-contagious skin disease that has no known cause or treatment. Various medical costs for skin disorders, including psoriasis, can be expensive and lifelong. The purpose of the present study was to determine the economic burden of psoriasis in patients admitted to general hospitals affiliated with Shiraz University of Medical Sciences, Iran in 2022.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>This research was a descriptive, cross-sectional, cost of illness study from a societal perspective. All psoriasis patients (<jats:italic>N<\/jats:italic>\u2009=\u2009118) admitted to the hospitals affiliated with Shiraz University of Medical Sciences in 2022 were examined. 7 participants refused to cooperate and were excluded from the study and, the information of 111 patients was collected. A researcher-made data collection form was used to collect data. A prevalence-based approach was used to prepare cost data, and the costing approach was bottom-up. The productivity lost due to the absenteeism of patients and their companions was estimated using the human capital approach. Microsoft Excel \u00ae 2016 was applied to analyze the data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean annual cost per psoriasis patient was estimated to be US$ 30,374.21. Its highest and lowest share was related to direct medical costs (88.61%), direct non-medical costs (7.3%) and indirect costs (4.09%), respectively. Also, the highest mean direct medical, direct non-medical, and indirect costs per patient were related to those of medicine (93.11%), transportation (51.65%), and absenteeism of the patients\u2019 companions due to patient care (71.73%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Considering that the major contributor in the direct medical cost of treating psoriasis patients was related to medicine, designing appropriate mechanisms for insurance coverage, and allocating government subsidies for the purchase of medicine, are suggested. The result of the current study has important implications for policymakers in developing guidelines for early diagnosis of this disease and reducing the health economic burden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13690-024-01332-2","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T08:02:00Z","timestamp":1720425720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Economic burden of psoriasis in Southern Iran in 2022"],"prefix":"10.1186","volume":"82","author":[{"given":"Ramin","family":"Ravangard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moslem","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Ghahartars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdosaleh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"1332_CR1","unstructured":"World Health Organization. Global report on psoriasis. World Health Organization; 2016. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/204417\/9789241565189_eng.pdf?sequence=1."},{"key":"1332_CR2","unstructured":"Nair PA, Badri T. Psoriasis. In: StatPearls. Treasure Island: StatPearls Publishing; 2023."},{"issue":"1","key":"1332_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4103\/jfmpc.jfmpc_689_19","volume":"9","author":"JP Rajguru","year":"2020","unstructured":"Rajguru JP, Maya D, Kumar D, Suri P, Bhardwaj S, Patel ND. Update on psoriasis: a review. J Family Med Prim Care. 2020;9(1):20\u20134.","journal-title":"J Family Med Prim Care"},{"key":"1332_CR4","unstructured":"Kerkhof Pvd, Nestle FO. Psoriasis. In: Dermatology e-book. 1. 3 ed. Elsevier Health Sciences; 2012."},{"issue":"19","key":"1332_CR5","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1001\/jama.2022.5270","volume":"327","author":"K Walter","year":"2022","unstructured":"Walter K. Psoriasis. JAMA. 2022;327(19):1936.","journal-title":"JAMA"},{"key":"1332_CR6","doi-asserted-by":"publisher","first-page":"743180","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8:743180.","journal-title":"Front Med (Lausanne)"},{"key":"1332_CR7","unstructured":"International Federation of Psoriasis Associations, International League of Dermatological Societies, International Psoriasis Council. Prevalence heat map. Global Psoriasis Atlas; 2021\u201323. Available from: https:\/\/www.globalpsoriasisatlas.org\/en\/explore\/prevalence-heatmap?metric=overall."},{"key":"1332_CR8","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IY, Kontopantelis E, Augustin M, Griffiths CE, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modeling study. BMJ. 2020;369:m1590.","journal-title":"BMJ"},{"issue":"6","key":"1332_CR9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","volume":"151","author":"EA Brezinski","year":"2015","unstructured":"Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651\u20138.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1332_CR10","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1007\/s12325-019-01049-7","volume":"36","author":"N Lopes","year":"2019","unstructured":"Lopes N, Dias LLS, Azulay-Abulafia L, Oyafuso LKM, Suarez MV, Fabricio L, et al. Humanistic and economic impact of moderate to severe plaque psoriasis in Brazil. Adv Ther (Weinh). 2019;36(10):2849\u201365.","journal-title":"Adv Ther (Weinh)"},{"issue":"5","key":"1332_CR11","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2340\/00015555-2329","volume":"96","author":"A Svedbom","year":"2016","unstructured":"Svedbom A, Dahl\u00e9n J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, et al. Economic burden of psoriasis and potential cost offsets with biologic treatment: a Swedish register analysis. Acta Derm Venereol. 2016;96(5):651\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1332_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.17576\/MH.2019.1401.02","volume":"14","author":"N Azizam","year":"2019","unstructured":"Azizam N, Saperi S, Aniza I, Norazirah M, Azura M, Zafar A, et al. Cost analysis of psoriasis treatment modalities in Malaysian public hospitals. Med Health. 2019;14(1):23\u201333.","journal-title":"Med Health"},{"issue":"3","key":"1332_CR13","first-page":"164","volume":"12","author":"E Zarei","year":"2021","unstructured":"Zarei E, Gholamhosseini A, Ghandi N. Estimation of direct and indirect costs of one-year treatment for psoriasis outpatients in Iran: a study in Razi hospital in 2017\u20132018. Dermatol Cosmet. 2021;12(3):164\u201379.","journal-title":"Dermatol Cosmet"},{"issue":"1","key":"1332_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12875-022-01719-6","volume":"23","author":"Y Avazeh","year":"2022","unstructured":"Avazeh Y, Rezaei S, Bastani P, Mehralian G. Health literacy and medication adherence in psoriasis patients: a survey in Iran. BMC Prim Care. 2022;23(1):1\u201311.","journal-title":"BMC Prim Care"},{"key":"1332_CR15","doi-asserted-by":"publisher","first-page":"100163","DOI":"10.1016\/j.jeoa.2018.09.002","volume":"17","author":"DE Bloom","year":"2020","unstructured":"Bloom DE, Chen S, Kuhn M, McGovern ME, Oxley L, Prettner K. The economic burden of chronic diseases: estimates and projections for China, Japan, and South Korea. J Econ Ageing. 2020;17:100163.","journal-title":"J Econ Ageing"},{"key":"1332_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.11604\/pamj.2023.44.6.35494","volume":"44","author":"TM Ipinnimo","year":"2023","unstructured":"Ipinnimo TM, Elegbede OE, Durowade KA, Adewoye KR, Ibirongbe DO, Ajayi PO, et al. Cost of illness of non-communicable diseases in private and public health facilities in Nigeria: a qualitative and quantitative approach. Pan Afr Med J. 2023;44:6.","journal-title":"Pan Afr Med J"},{"issue":"1","key":"1332_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.healthpol.2005.07.016","volume":"77","author":"R Tarricone","year":"2006","unstructured":"Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy. 2006;77(1):51\u201363.","journal-title":"Health Policy"},{"issue":"4","key":"1332_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327\u201337.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"1332_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3350\/kjhep.2011.17.4.258","volume":"17","author":"KS Lee","year":"2011","unstructured":"Lee KS. A tool for communication with decision-makers: limitations and utilization of studies on cost of illness. Korean J Hepatol. 2011;17(4):258\u201360.","journal-title":"Korean J Hepatol"},{"issue":"1","key":"1332_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13023-021-01815-3","volume":"16","author":"L Garc\u00eda-P\u00e9rez","year":"2021","unstructured":"Garc\u00eda-P\u00e9rez L, Linertov\u00e1 R, Valc\u00e1rcel-Nazco C, Posada M, Gorostiza I, Serrano-Aguilar P. Cost-of-illness studies in rare diseases: a scoping review. Orphanet J Rare Dis. 2021;16(1):178.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"1332_CR21","first-page":"156","volume":"48","author":"E Seyedrezazadeh","year":"2023","unstructured":"Seyedrezazadeh E, Gilani N, Ansarin K, Yousefi M, Sharifi A, Jafari Rouhi AH, et al. Economic burden of asthma in northwest Iran. Iran J Med Sci. 2023;48(2):156\u201366.","journal-title":"Iran J Med Sci"},{"issue":"1","key":"1332_CR22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1186\/s12913-022-07936-0","volume":"22","author":"M Aoun","year":"2022","unstructured":"Aoun M, Helou E, Sleilaty G, Zeenny RM, Chelala D. Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives. BMC Health Serv Res. 2022;22(1):586.","journal-title":"BMC Health Serv Res"},{"issue":"02","key":"1332_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4236\/health.2021.132009","volume":"13","author":"RN Tekin","year":"2021","unstructured":"Tekin RN, \u015eahin B. Comparison of top-down and bottom up cost approaches in colon and rectal cancer treatment. Health. 2021;13(02):90.","journal-title":"Health"},{"key":"1332_CR24","unstructured":"Central Bank of Islamic Republic of Iran. Foreign exchange rates. Central Bank of IRI; 2022. Available from: https:\/\/cbi.ir\/ExRates\/rates_en.aspx."},{"issue":"Suppl 1","key":"1332_CR25","doi-asserted-by":"publisher","first-page":"i89","DOI":"10.1136\/ard.2009.117150","volume":"69","author":"W Van den Hout","year":"2010","unstructured":"Van den Hout W. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89\u201391.","journal-title":"Ann Rheum Dis"},{"key":"1332_CR26","unstructured":"Ministry of Cooperatives Labor and Social Welfare Islamic Republic of Iran. Circular. Ministry of Cooperatives Labor and Social Welfare of IRI; 2022. Available from: https:\/\/www.mcls.gov.ir\/icm_content\/media\/image\/2022\/03\/527670_orig.pdf."},{"key":"1332_CR27","unstructured":"Microsoft Corporation. Microsoft Excel. 2016. Retrieved from https:\/\/office.microsoft.com\/excel."},{"issue":"1","key":"1332_CR28","doi-asserted-by":"publisher","first-page":"2247106","DOI":"10.1080\/09546634.2023.2247106","volume":"34","author":"S Min","year":"2023","unstructured":"Min S, Wang D, Xia J, Lin X, Jiang G. The economic burden and quality of life of patients with psoriasis treated with biologics in China. J Dermatolog Treat. 2023;34(1):2247106.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"1332_CR29","doi-asserted-by":"publisher","first-page":"e78152","DOI":"10.1371\/journal.pone.0078152","volume":"8","author":"SI Steinke","year":"2013","unstructured":"Steinke SI, Peitsch WK, Ludwig A, Goebeler M. Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy. PLoS One. 2013;8(10):e78152.","journal-title":"PLoS One"},{"key":"1332_CR30","unstructured":"Moradi M. Health-related quality of life and disease burden of psoriasis in Iran [Ph.D. Thesis]. CORVINUS University of Budapest; 2017."},{"issue":"1","key":"1332_CR31","first-page":"37","volume":"12","author":"R Amiri","year":"2021","unstructured":"Amiri R, Mohamadi S, Khalili M, Fatehi A, Sabermahany A, Aflatoonian M. Teatment costs of patients admitted in dermatologic ward of Afzalipour hospital, Kerman. J Dermatol Cosmet. 2021;12(1):37\u201343.","journal-title":"J Dermatol Cosmet"},{"key":"1332_CR32","first-page":"89","volume":"12","author":"S L\u00f6fvendahl","year":"2022","unstructured":"L\u00f6fvendahl S, Norlin JM, Schmitt-Egenolf M. Economic burden of generalized pustular psoriasis in Sweden: a population-based register study. Psoriasis (Auckl). 2022;12:89\u201398.","journal-title":"Psoriasis (Auckl)"},{"issue":"12","key":"1332_CR33","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1365-4632.2011.05359.x","volume":"51","author":"AR Levy","year":"2012","unstructured":"Levy AR, Davie AM, Brazier NC, Jivraj F, Albrecht LE, Gratton D, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012;51(12):1432\u201340.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1332_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s13555-014-0053-2","volume":"4","author":"A Mustonen","year":"2014","unstructured":"Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R. Psoriasis causes significant economic burden to patients. Dermatol Ther (Heidelb). 2014;4(1):115\u201324.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1332_CR35","unstructured":"Badie S, Nasr T. Investigating and analyzing the accommodation of patient companions in Shiraz hospitals with the attitude of reducing companionship. In: National technology conference in applied engineering. Tehran; 2017."}],"container-title":["Archives of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-024-01332-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13690-024-01332-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13690-024-01332-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T08:07:52Z","timestamp":1720426072000},"score":1,"resource":{"primary":{"URL":"https:\/\/archpublichealth.biomedcentral.com\/articles\/10.1186\/s13690-024-01332-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1186\/s13690-024-01332-2","relation":{},"ISSN":["2049-3258"],"issn-type":[{"value":"2049-3258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present research was approved by the Ethics Committee of Shiraz University of Medical Sciences (Code: IR.SUMS.NUMIMG.REC.1402.010). The patients were free to choose to participate in the study; the research objectives were explained to them and their informed consent was obtained. The data collection forms were completed anonymously, and the patients were assured of the confidentiality of their answers. In order to comply with ethical considerations and the confidentiality of the patients\u2019 information, they were distinguished by the codes at the top of the data collection form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}